Truseltiq and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Truseltiq (infigratinib).
Infigratinib Food
Major Food Interaction
Infigratinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with infigratinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Switch to professional interaction data
Truseltiq drug interactions
There are 207 drug interactions with Truseltiq (infigratinib).
Truseltiq disease interactions
There are 4 disease interactions with Truseltiq (infigratinib) which include:
More about Truseltiq (infigratinib)
- Truseltiq consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Ziihera
Ziihera (zanidatamab) is a bispecific HER2-directed antibody used to treat HER2-positive biliary ...
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Lytgobi
Lytgobi (futibatinib) is used for the treatment of bile duct cancer (intrahepatic ...
Pemigatinib
Pemigatinib systemic is used for cholangiocarcinoma, myeloid/lymphoid neoplasms
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.